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The Tec family member Bruton’s tyrosine kinase (Btk) is a cytoplasmic protein tyrosine kinase that transduces signals from the
pre-B and B cell receptor (BCR). Btk is involved in pre-B cell maturation by regulating IL-7 responsiveness, cell surface phenotype
changes, and the activation of  L chain gene rearrangements. In mature B cells, Btk is essential for BCR-mediated proliferation
and survival. Upon BCR stimulation, Btk is transphosphorylated at position Y551, which promotes its catalytic activity and
subsequently results in autophosphorylation at position Y223 in the Src homology 3 domain. To address the significance of Y223
autophosphorylation and the requirement of enzymatic activity for Btk function in vivo, we generated transgenic mice that express
the autophosphorylation site mutant Y223F and the kinase-inactive mutant K430R, respectively. We found that Y223 autophos-
phorylation was not required for the regulation of IL-7 responsiveness and cell surface phenotype changes in differentiating pre-B
cells, or for peripheral B cell differentiation. However, expression of the Y223F-Btk transgene could not fully rescue the reduction
of  L chain usage in Btk-deficient mice. In contrast, transgenic expression of kinase-inactive K430R-Btk completely reconstituted
 usage in Btk-deficient mice, but the defective modulation of pre-B cell surface markers, peripheral B cell survival, and BCR-
mediated NF-B induction were partially corrected. From these findings, we conclude that: 1) autophosphorylation at position
Y223 is not essential for Btk function in vivo, except for regulation of  L chain usage, and 2) during B cell development, Btk
partially acts as an adapter molecule, independent of its catalytic activity. The Journal of Immunology, 2003, 171: 5988–5996.
B ruton’s tyrosine kinase (Btk)3 is a member of the Tecfamily of cytoplasmic protein tyrosine kinases (PTK) andplays an essential role in B lymphocyte development and
function (1, 2). Together with two other types of nonreceptor PTK,
Syk and the Src family member Lyn, Btk acts as an important
transducer of signals originating from the pre-B cell receptor (pre-
BCR) and the BCR.
The pre-BCR complex, which is comprised of  H chain, the
nonrearranging VpreB and 5 surrogate L chain (SLC) proteins,
and the Ig-/CD79a and Ig-/CD79b signaling components, is a
key checkpoint in B cell development to monitor the expression of
a functional Ig  H chain (3, 4). Pre-BCR expression is essential
for the proliferative expansion of cytoplasmic  H chain-positive
pre-B cells and the induction of progression into small pre-B cells
in which Ig L chain rearrangement occurs (3, 4). Pre-BCR engage-
ment leads to the formation of a lipid raft-associated calcium signaling
module composed of the tyrosine-phosphorylated signaling molecules
Lyn, Syk, B cell linker protein (BLNK)/SLP-65, phosphoinositide
3-kinase, Btk, Vav, and phospholipase C2 (PLC-2) (5).
The importance of Btk in pre-BCR checkpoint function in hu-
mans is evidenced by an almost complete arrest of B cell differ-
entiation due to defective expansion of the earliest cytoplasmic 
H chain-positive pre-B cells in X-linked agammaglobulinemia
(XLA) patients with mutations in the Btk gene (6, 7). XLA is
characterized by an almost complete absence of peripheral B cells
and plasma cells; serum levels of all Ig classes are very low. In
contrast, mice with a targeted mutation in the Btk gene or CBA/N
mice, which carry an R28C point mutation in the Btk pleckstrin
homology (PH) domain, exhibit a milder disorder, x-linked immu-
nodeficiency (xid), mainly reflecting poor survival of peripheral B
cells (8–10). Btk-deficient mice manifest a specific arrest of pe-
ripheral B cell development within the immature B cell pool at the
progression of IgMhigh to IgMlow AA4CD23 transitional B cells
(8–12). In these mice, the numbers of pre-B cells that are gener-
ated in the bone marrow (BM) are normal (8, 9, 13). Nevertheless,
Btk is crucially involved in the regulation of the developmental
progression of pre-B cells by limiting the IL-7-driven expansion of
large cycling pre-B cells (14, 15). In in vitro BM cultures, Btk-
deficient pre-B cells showed increased IL-7-driven expansion and
reduced developmental progression of large cycling into small
resting pre-B cells and subsequently into Ig B cells (14). In ad-
dition, we recently demonstrated that Btk cooperates with the
BLNK/SLP adapter molecule as a tumor suppressor that limits
pre-B cell expansion (15). During the transition of large cycling to
small resting cytoplasmic  pre-B cells in the mouse, Btk-defi-
cient cells fail to efficiently modulate the expression of SLC, the
metallopeptidase BP-1, the adhesion molecule CD2, the IL-2R
CD25, and the membrane sialoglycoprotein CD43 (14). Btk-defi-
cient cells manifest a specific developmental delay within the
small pre-B cell compartment of 3 h in vivo. The finding of
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reduced  L chain usage in Btk-deficient mice implicates Btk in
the regulation of the activation of the  locus for V(D)J recombi-
nation in pre-B cells (16).
Btk contains five distinct domains: an N-terminal PH domain, a
Tec homology (TH) domain, a Src homology 3 (SH3) domain, an
SH2 domain, and a C-terminal catalytic domain (Fig. 1A). Upon
BCR stimulation, Btk activation is initiated by targeting the kinase
to the plasma membrane through interactions of its PH domain
with phosphatidylinositol-3,4,5-triphosphate, a second messenger
generated by phosphoinositide 3-kinase (17, 18). In concert, the
Lyn and Syk kinases are activated, resulting in transphorylation of
Btk at position Y551, which promotes the catalytic activity of Btk
and subsequently results in its autophosphorylation at position
Y223 in the SH3 domain (Fig. 1A) (19, 20). Although Y223 phos-
phorylation has little discernible influence on Btk catalytic activity,
it prevents binding to Wiskott Aldrich syndrome protein (WASP)
and increases the affinity to Syk (21). Concomitantly, Syk activa-
tion results in phosphorylation of BLNK/SLP65, which allows for
the association of this adapter molecule with the Btk SH2 domain
and with PLC-2 (2, 22). These interactions are critical to the
activity of Btk and result in PLC- tyrosine phosphorylation, ino-
sitol triphosphate production, and calcium mobilization.
Although biochemical studies in cultured B cells and fibroblasts
have provided important insights into the molecular mechanism of
BCR-mediated Btk activation, these systems have not allowed for
the investigation of the role of the individual Btk domains in (pre-)
BCR checkpoint functions in vivo. In this study, we addressed the
functional significance of Btk Y223 autophosphorylation and in-
vestigated whether Btk can also act as an adapter molecule,
independent of its catalytic activity. Therefore, we generated
transgenic mouse strains that express the autophosphorylation site
mutant Y223F-Btk and K430R kinase-inactive Btk, under the
control of the B cell-specific CD19 promoter region. We crossed
these mice onto a Btk null background (10), and examined the in
vivo effects of the Y223F and K430R mutations, in particular with
respect to Ig  L chain usage, pre-B cell surface marker modula-
tion, and the proliferative response of pre-B cells to IL-7.
Materials and Methods
Generation of Btk-transgenic mice
Wild-type (WT)-Btk transgenic mice have been described previously (23).
The human Btk transgenes consist of a 6.3-kb genomic fragment con-
taining the CD19 promoter region, a 0.3-kb fragment with the first three
exons of human Btk as cDNA sequence, as well as a 27.1-kb genomic
DNA fragment, encompassing the Btk exons 3–19 (23). Using double-
stranded site-directed mutagenesis (Stratagene, La Jolla, CA), the Y223F
and K430R mutations were introduced into the constructs that were pre-
viously used to generate the WT-Btk mice (23).
The Y223F mutation was created by replacement of AT by TC in exon
8 of human Btk in a 2.8-kb Cfr10I-Asp718 fragment (containing exons
8–11) in pBlueScript, using a mutation primer (5-GCTGAAAAAGGTT
GTGGCCCTTTTCGATTACATGCCAATG-3) and a 39-bp KpnI-BglII
selection primer. The mutated Cfr10I-Asp718 fragment was subsequently
cloned into the WT-Btk transgene construct. The A-to-G replacement mu-
tation K430R in exon 14 was created in a 2.1-kb Asp718-MunI fragment
encompassing human Btk exon 12–14. A 40-bp mutation primer,
5-CCAGTAGGACGTGGCCATCAGGATGATCAAAGAAGGCTCC-3
and the 39-bp KpnI-BglII selection primer was used. The mutated 2.1-kb
Asp718-MunI fragment was ligated to a 9.2-kb MunI-Asp718 fragment, to
yield a 11.3-kb Asp718 human Btk fragment, which was used to replace
the 11.3-kb Asp718 fragment in the WT-Btk construct (23).
The 34-kb MluI-NotI inserts from the Y223F-Btk and K430R-Btk
constructs were excised from the vector, gel purified, and microinjected
into the pronuclei of FVB-fertilized oocytes. Transgenic founder mice were
identified by Southern blotting and crossed with Btk null mice (10), which
were bred onto a C57BL/6 background for more than eight generations.
Sequence fidelity of the mutated fragments was confirmed, both in plasmid
DNA before subsequent cloning steps and in genomic DNA obtained from
the F1 transgenic mice generated. All mice were bred and maintained at the
Erasmus MC animal care facility under specific pathogen-free conditions.
Mouse genotyping
Tail DNA was analyzed by Southern blotting of BamHI digests using a
partial human Btk cDNA probe (bp 133-1153), as described previously
(10, 23). Alternatively, the presence of Btk transgenes was evaluated by
PCR, using the following primers: CD19prom, 5-TGCAATTAGTGGT
GAACAAC-3, and hmBtk.65R, 5-AGATGCCAGGACTTGGAAGG-3.
Endogenous mouse Btk WT alleles were identified by an exon 9 forward
primer (5-CACTGAAGCTGAGGACTCCATAG-3) and an exon 10 re-
verse primer (5-GAGTCATGTGCTTGGAATACCAC-3). For Btk




Preparations of single-cell suspensions, standard and intracellular flow cy-
tometry, and conjugated mAbs (BD PharMingen, Sunnyvale, CA) have
been described previously (10, 14). The anti-SLC hybridoma LM34 (24)
was kindly provided by A. Rolink (Basel, Switzerland); Abs were purified
using protein G columns and conjugated to biotin according to standard
procedures. Mice were analyzed at the age of 8–16 wk. Transgenic Btk
expression levels were quantified by intracellular flow cytometry, using
affinity-purified polyclonal rabbit anti-Btk (BD PharMingen) and FITC-
conjugated goat anti-rabbit Ig (Nordic, Capistrano Beach, CA). Median
fluorescence intensity (MFI) values were obtained by CellQuest software
(BD Biosciences, San Diego, CA), whereby values for transgenic human
Btk and endogenous murine Btk were corrected for background fluores-
cence, as detected in Btk null mutant mice. Subsequently, the ratio of the
MFI values of transgenic Btk over endogenous Btk was calculated.
In vitro (pre-)B cell cultures
IL-7-driven BM cultures and determination of IL-7-dependent proliferative
responses of total BM cells have been described previously (14, 16). Ma-
ture B cell fractions were purified from spleen, using standard NH4Cl lysis
to deplete erythrocytes, followed by complement-mediated T cell lysis, as
described previously (25). The enriched B cell fractions were cultured in
vitro in the presence or absence of LPS, 5 g/ml anti-CD40, or polyclonal
goat anti-mouse IgM (Southern Biotechnology Associates, Birmingham,
AL), as described previously (16). To measure DNA synthesis, cells were
pulsed with [3H]thymidine for 16–20 h, harvested, and counted using stan-
dard methods. For apoptosis assays, DNA content was determined in eth-
anol-fixed cells, using propidium iodide.
B cell stimulation and Western blotting analyses
For analyses of nuclear c-Rel expression, single-cell suspensions from
spleen were depleted of erythrocytes by NH4Cl lysis and enriched for B
cells by AutoMACS purification, using biotinylated Abs to Gr-1, Ter119,
CD4, CD8, and CD11b and magnetic streptavidin MicroBeads (Miltenyi
Biotec, Sunnyvale, CA) for negative selection. Cells were stimulated with
10 g/ml F(ab)2 of polyclonal goat anti-mouse IgM (Jackson ImmunoRe-
search, West Grove, PA) in RPMI 1640 at 37°C for 4 h. Total nuclear and
cytoplasmic protein extracts were prepared according to Andrews and
Faller (26). Samples from equivalent cell numbers were resolved by SDS-
PAGE, and proteins were transferred to nitrocellulose membrane, as de-
scribed (10). Membranes were blocked with 5% milk in TBS/0.05% Tween
20 for 1 h and incubated overnight with anti c-Rel (SC-071; Santa Cruz
Biotechnology, Santa Cruz, CA), and subsequently with HRP-conjugated
swine anti-rabbit Ig. Densitometry analysis was conducted using Image-
Quant analysis software (Molecular Dynamics, Sunnyvale, CA).
For analyses of Bcl-xL and cyclin D2 induction, total splenocytes were
depleted of erythrocytes and stimulated with 10 g/ml polyclonal goat
anti-mouse IgM (Southern Biotechnology Associates) in RPMI 1640/10%
FCS at 37oC. Total cell lysates were subjected to SDS-PAGE using stan-
dard procedures (27). Immunoblotting Abs used included: anti-Bcl-xL
(2762; Cell Signaling Technology, Beverly, MA), anti-cyclin D2 (M-20;
SC-593; Santa Cruz Biotechnology), and anti-extracellular signal-regu-
lated kinase 1/2 (SC-094; Santa Cruz Biotechnology).
For analysis of Btk expression and Btk in vitro kinase assays, single-cell
suspensions from spleen were depleted of erythrocytes and enriched for B
cells by AutoMACS purification. B cell fractions were stimulated, as de-
scribed above, for 5 and 10 min. Anti-Btk C-20 (Santa Cruz Biotechnol-
ogy) was used for immunoblotting, while a polyclonal rabbot anti-Btk
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(kindly provided by V. Tybulewicz, London, U.K.) was used for immu-
noprecipitation. In vitro kinase assays were performed, as described pre-
viously (27).
Ig detection and in vivo immunizations
Levels of Ig subclasses in serum were measured by sandwich ELISA, as
described previously (25). To measure thymus-independent responses,
mice were injected i.p. with 50 g of trinitrophenol (TNP)-Ficoll in PBS,
and TNP-specific IgM and IgG3 were analyzed at day 7 in a TNP-specific
ELISA (28).
Results
Expression of Btk mutants in transgenic mice
We have previously described transgenic mice that express WT
human Btk under the control of the CD19 promoter region (23).
When these mice were mated onto a Btk-deficient background,
correction of all xid features was observed, indicating that in this
system the Btk gene was appropriately targeted to both conven-
tional and CD5 B-1 cells. We now generated mouse strains, ex-
pressing Y223F (n  5) and K430R (n  2) mutant Btk. These
mice were crossed onto the Btk null background, and transgenic
Btk protein expression was quantified by intracellular flow cytom-
etry. Median fluorescence intensities of transgenic Btk were com-
pared with endogenous Btk in B-lineage subpopulations (Fig. 1B;
Table I). The different mouse lines exhibited a wide range of Btk
protein expression levels, which were directly correlated with the
transgene copy number, as estimated by Southern blotting analyses
of genomic DNA samples from the mice. The expression of trans-
genic Btk increased as the B cell progenitors in the BM matured to
surface Ig-expressing peripheral B cells (Table I). Expression of
transgenic Btk protein was confirmed by Western blotting analysis
of BM and spleen cell suspensions, in which Btk protein was vis-
ible as a single 77-kDa band for all transgenic lines generated
(data not shown). Because we aimed to investigate the role of Btk
in particular at the pre-B cell to immature B cell progression, we
mainly focused on those mouse strains that expressed physiolog-
ical levels of transgenic Btk (1–2  endogenous levels) in imma-
ture B cells in the BM. These transgenic lines, AM-02 (Y223F)
and XK-24 (K430R), expressed high Btk levels in mature IgD
peripheral B cells (Table I).
B cell development in Btk mutant mice
To determine the effect of the Btk mutations on B cell develop-
ment, we examined the size of the B cell subpopulations in spleen,
peritoneal cavity, and BM in the mutant mice by flow cytometry.
In these experiments, we also included WT-Btk transgenic mice,
as well as nontransgenic Btk and Btk littermates, which served
as controls.
The xid phenotype in Btk mice is characterized by a specific
deficiency of mature IgMlowIgDhigh cells in the spleen and lack of
CD5 B-1 cells in the peritoneal cavity (8–10) (see Fig. 2, A and
B). The only obvious difference between the BM B cell subpopu-
lations of Btk-deficient and control Btk mice is that the subpopu-
lation of mature B220high-recirculating cells is reduced and has an
aberrant IgMhigh phenotype (Fig. 2C). We previously reported (23)
that CD19 promoter-driven human WT-Btk expression restores
these defects. We did not detect a significant effect of the Y223
autophosphorylation site mutation, as also the expression of
Y223F-Btk appeared to restore B cell numbers completely in
spleen, peritoneal cavity, and BM (Fig. 2, A–C). Expression of low
levels of Y223F-Btk (line AM-05) (20% of normal in immature
B cells, not detectable with our flow cytometric assay) on the Btk
null background rescued the presence of peritoneal CD5 B-1
cells, but not the numbers or surface profile of splenic B cells (data
not shown). Considerable overexpression of Y223F-Btk (line UK-
21, 14 in immature B cells) was associated with deletion of
IgMhigh immature B cells in the BM (data not shown), similar to
our previous findings in transgenic mice expressing the constitu-
tive active Btk-mutant E41K (23).
Interestingly, reconstitution with kinase-inactive K430R-Btk
partially overcame the block in peripheral B cell maturation, when
significantly overexpressed. In these mice, the fraction of mature
IgMlowIgDhigh B cells in the spleen was partially restored (16%,
FIGURE 1. Expression of Btk mutant transgenes during B cell devel-
opment. A, Domains of Btk. The positions of the mutations and Btk-asso-
ciated molecules are shown. The numbers represent the amino acid posi-
tions of the domain boundaries. B, Intracellular Btk expression in the
indicated B-lineage subpopulations in BM and spleen. B220 cells were
gated and B-lineage subpopulations were defined on the basis of surface
IgM/IgD expression (left) and analyzed for intracellular Btk expression
(right). The results are displayed as histograms of a wild-type mouse
(Btk; thin lines) and a Y223F-Btk mutant transgenic mouse (AM-02; bold
lines), compared with the background staining, as determined in Btk mice
(dashed lines). The values for the differences in MFI (MFI) are given.
MZ  marginal zone.
Table I. Overview of transgenic lines expressing mutant Btk
Btk Mutant Tg Line
Relative Expression Levela
Pro-/pre-B Immature B Mature B
WT NR-02b 0.2 1.2 6.9
Y223F AM-05 0.2 0.2 0.2
AM-03 0.2 0.45 2.7
AM-02 0.37 1.9 10
TK-20 0.40 2.6 11
UK-21 5.8 14 37
K430R YK-25 0.2 0.20 0.54
XK-24 0.2 0.92 17
a As determined by intracellular flow cytometry. The median fluorescence inten-
sities in the different B-lineage cell fractions of wild-type mice were set to 1.0.
b These mice were described previously (23).
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compared with 7% in Btk mice and 30% in WT transgenic
mice, Fig. 2A), and B220highIgMlow-recirculating cells appeared in
the BM (Fig. 2C). However, we still did not detect CD5 B-1 cells
in the peritoneum (Fig. 2B). When present on the Btk back-
ground, overexpression of K430R-Btk did not appear to result in
adverse effects on B cell development (data not shown), indicating
that in this respect the K430R-Btk did not act as a dominant-
negative mutant.
Collectively, these findings show that expression of Y223F-Btk
restored B cell development, indicating that Y223 autophosphor-
ylation is not essential for the function of Btk signaling in directing
B cell development. The limited, but detectable, correction of the
xid phenotype in K430R transgenic mice indicates that Btk func-
tion is partly independent of its intrinsic enzymatic activity. Fi-
nally, the analyses showed that B-1 B cell development is sup-
ported by low levels of Y223F-Btk, but not by kinase-inactive Btk.
Ig  L chain usage in Btk mutant mice
We previously showed that B cells from Btk-deficient mice have a
50% reduction in the frequency of Ig  L chain expression, al-
ready at the immature B cell stage in the bone marrow (16). This
finding implicated Btk in the regulation of the activation of the 
locus for V(D)J recombination in pre-B cells (16).
To investigate the effects of the Y223F and K430R mutations on
the ability of Btk to regulate  usage, we analyzed immature
B220lowIgMIgD B cells from the BM of a panel of Btk, Btk,
and transgenic Btk mutant mice by four-color flow cytometry (Ta-
ble II). Consistent with our previous report (16), we found reduced
 usage in Btk mice, when compared with Btk or WT-Btk
transgenic mice (Table II). In Y223F-Btk mice,  usage was still
significantly reduced, when compared with Btk mice (Table II)
or with WT-Btk transgenic mice, which showed normal propor-
tions of  B cells (16). Thus, transgenic expression of physio-
logical levels of Y223F-Btk could only partially correct  usage in
Btk mice. Unexpectedly, expression of K430R-Btk fully recon-
stituted  usage, as in K430R-Btk mice the proportions of  L
chain-expressing cells were similar to those in control Btk mice.
In summary, these findings indicate the differential requirement
for Btk domains in the regulation of  L chain usage: the Y223
autophosphorylation site is important, but kinase activity does not
appear to be critical. We conclude that in the context of the control
of  usage in early B cell development, Btk mainly functions as an
adapter molecule, independent of its enzymatic activity.
Pre-B cell maturation in Btk mutant mice
We previously showed that during the developmental progression
of large cycling into small resting cytoplasmic  pre-B cells,
Btk-deficient cells fail to efficiently down-regulate the expression
of BP-1 and SLC and up-regulate the expression of surface CD2
and CD25/IL-2R (14). To investigate the requirement for the dif-
ferent Btk domains in the modulation of these phenotypic markers,
we analyzed their expression profile in pre-B cells and immature B
cells from Btk mutant mice by flow cytometry.
As shown in Fig. 3A, Btk-deficient pre-B cells have significantly
higher levels of cytoplasmic SLC and BP-1, but lower expression
levels of CD2 and CD25. This aberrant marker profile was fully
corrected in transgenic mice expressing WT or Y223F Btk (Fig.
3A). By contrast, expression of K430R-Btk only partially restored
Btk function in pre-B cell differentiation, as the expression levels
of BP-1, cSLC, CD2, and CD25 in pre-B cells were intermediate
between the values for Btk and Btk mice (Fig. 3, A and B).
Also, at the next developmental stage of immature B cells, the
expression profiles of the BP-1, cSLC, CD2, and CD25 markers
were fully corrected in WT and Y223F Btk mice and partially
corrected in K430R-Btk mice (data not shown, and Fig. 3C).
In summary, these findings demonstrate that the function of Btk
in vivo in the induction of cell surface phenotype changes in cy-
toplasmic  pre-B and immature B cells is not affected by loss of
the Y223 autophosphorylation site and is only partially dependent
on its kinase activity.
FIGURE 2. Flow cytometric analysis of B cell populations in Btk mu-
tant mice. A, Surface IgM/IgD expression in the spleen with total splenic
B cell numbers as mean values 	 SEM. B, Surface CD19/CD5 expression
in the peritoneal cavity. C, Surface IgM/B220 expression in the BM. Total
lymphocytes were gated on the basis of forward and side scatter charac-
teristics. Data are displayed as dot plots, and the percentages of cells within
the indicated gates are given. Data shown are representative of 5–20 ani-
mals examined within each group.
5991The Journal of Immunology
Proliferative responses to IL-7 in Btk mutant mice
Btk has an inhibitory effect on the proliferation of B cell precursors
in long-term Whitlock-Witte BM cultures and in IL-7-driven cul-
tures of BM or fetal liver cells (14, 29, 30). In [3H]thymidine
incorporation experiments, after 5 days of culture in the presence
of IL-7, Btk-deficient total BM cells showed significantly higher
proliferative responses when compared with Btk cells (Fig. 4A).
Expression of WT or Y223F Btk exhibited a similar inhibitory
effect on IL-7-driven proliferation as intact endogenous Btk. Pro-
liferative responses to IL-7 in K430R mutant mice were only
slightly higher than those found in Btk mice. Therefore, we con-
clude that the function of Btk in down-regulation of IL-7-driven
proliferation is not critically affected by loss of Y223 autophos-
phorylation or kinase activity of Btk.
Developmental progression of Btk mutant pre-B cells in vitro
In Btk-deficient pre-B cells, the increased IL-7-driven proliferation
in vitro is accompanied by reduced developmental progression
from large cycling CD2 pre-B cells into noncycling small resting
CD2 pre-B cells, and subsequently into surface Ig B cells (14).
To analyze the function of Btk domains in this context, total BM
cell suspensions from the panel of mutant mice were cultured in
the presence of 100 U/ml IL-7. At day 5, the distribution of B220
cells over six developmental fractions,  pro-B cells, CD2 
large cycling pre-B cells, CD2  small pre-B cells, CD2 
small pre-B cells, IgMIgD immature B cells, and IgMIgD
mature B cells, was evaluated by flow cytometry (Fig. 4B). Con-
sistent with our previous findings (14), we noticed that in the ab-
sence of Btk: 1) growth of cytoplasmic  cells was hardly sup-
ported, 2) progression from the CD2 into the CD2 pre-B cell
stage was impaired, and 3) the proportions of IgM immature and
mature B cells were reduced, when compared with wild-type mice.
The BM cultures from WT and Y223F Btk mice exhibited a sub-
population distribution that was similar to that in Btk control
mice. Expression of the K430R-Btk transgene partly restored Btk
function, as in the K430R cultures significant fractions of 
pro-B cells were found and CD2 expression was more efficiently
induced on  small pre-B cells, when compared with cultures
from Btk-deficient mice (Fig. 4B).
Taken together, these results show that the role of Btk signaling
in the induction of the developmental progression of CD2 into
CD2 small pre-B cells and subsequently to surface Ig B cells in
vitro is completely independent of Y223 autophosphorylation. In
this context, kinase-inactive Btk is apparently partially active.
Kinase-independent adapter function of Btk in mature B cells
Because kinase-inactive Btk could partially restore developmental
progression of pre-B cells, we examined mature B cell function in
K430R-Btk mice to evaluate the overall ability of kinase-inactive
Btk to complement other features of the xid phenotype.
Btk-deficient mice have severely decreased levels of IgM and
IgG3 in the serum and do not mount specific Ab responses to T
cell-independent type II (TI-II) Ags in vivo, and xid B cells un-
dergo apoptosis instead of proliferation in response to in vitro
stimulation (8, 9, 31–33). The K430R-Btk transgene provided a
significant correction of the decreased levels of IgM in the serum
of Btk-deficient mice, while only a modest increase in IgG3 was
observed (Fig. 5A). Expression of K430R-Btk in Btk-deficient
mice did not reconstitute the in vivo responsiveness of B cells to
the TI-II Ag TNP-Ficoll. Moreover, K430R-Btk expression on a
wild-type background even showed a dominant-negative effect on
the production of TNP-specific IgM (Fig. 5B).
When purified splenic B cell suspensions were stimulated in
vitro, K430R-Btk completely restored the proliferative responses
to anti-CD40 and LPS (Fig. 6A), which are known to be affected
FIGURE 3. Phenotypic characterization of pre-B and immature B cells
in Btk mutant mice. A, Expression profiles of cytoplasmic SLC, surface
BP-1, CD2, and CD25 in pre-B cells of the indicated mice. Flow cytometry
data are displayed as filled histograms, with background stainings of
B220 cells (dashed lines) as negative controls. The percentages of posi-
tive cells are indicated. Data shown are representative of 5–20 animals
examined within each group. B and C, The K430R-Btk transgene partially
corrects the expression of the indicated markers in pre-B cells (B) and
B220lowIgM immature B cells (C). Differences between Btk and Btk
pre-B and immature B cells were significant for all markers (t test; p 
0.005). Asterisks indicate significance of differences between K430R-Btk
and Btk mice (, p  0.05; , p  0.0005). Cytoplasmic SLC and CD2
expression was investigated in B220lowIgMc pre-B cells, while BP-1
and CD25 were analyzed in total B220lowIgM pro-B/pre-B cell fractions
(pro-B cells have very low proportions of BP-1 or CD25 cells).
Table II. Ig  L chain usage in Btk mutant mice
Btk Mutant na
Ig  Immature B
Cells (%) p Valuesb
Btk 32 7.7 	 0.5c
Btk 24 2.9 	 0.3 109
Y223F 12 4.9 	 0.5 0.0017
K430R 19 7.5 	 0.7 NS
a Number of mice per group.
b Values of p for difference with the group of Btk mice.
c Mean values 	 SEM.
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by defective Btk function (8, 9, 34). In contrast, the rescue of the
proliferative response to anti-IgM stimulation was modest (Fig.
6A). To determine the effect of the K430R-Btk transgene on B cell
survival, purified splenic B cells from Btk, Btk, WT-Btk, and
K430R-Btk mice were cultured in vitro in medium alone, or in the
presence of anti-CD40, LPS, or anti-IgM. After 40 h, cells were
stained with propidium iodide and examined by flow cytometry to
determine the fraction of apoptotic cells, i.e., cells with sub-G1
amounts of DNA. The presence of the K430R-Btk transgene on the
Btk null background strongly reduced the proportion of apoptotic
cells, in all four culture conditions (Fig. 6B). Apoptosis levels of
K430R-Btk B cells stimulated with anti-IgM were intermediate
between the values for wild-type and Btk-deficient mice. Taken
together, these data indicate that kinase-inactive Btk can partially
rescue the compromised cell cycle induction and cell survival of
Btk-deficient mature B cells.
Kinase-inactive Btk induces NF-B activation upon BCR
stimulation
To explore the mechanism underlying the kinase-independent
adapter function of Btk, we further investigated kinase-inactive
Btk function in BCR signal transduction. Consistent with a previ-
ous report (19), in vitro kinase assays of immunoprecipitated Btk
from purified splenic B cell fractions stimulated with anti-IgM Abs
confirmed that K430R-mutated Btk did not have any detectable
autophosphorylation activity, even though high levels of K430R-
Btk were expressed (Fig. 7A).
Btk is known to have a critical role in BCR-directed cell cycle
induction (32, 33, 35), as well as nuclear translocation of NF-B,
which induces expression of the antiapoptotic survival protein
Bcl-xL (31, 33, 36, 37). We thus evaluated the ability of K430R-
Btk to activate NF-B and induce Bcl-xL and cyclin D2 expression
in response to BCR engagement. Western blot analysis of purified
splenic B cells that were stimulated with anti-IgM Abs for 4 h
showed that, while induction of nuclear c-Rel was negligible in
Btk-deficient B cells, the fold inductions in K430R-Btk were close
to those observed in Btk control mice (Fig. 7B). Under these
conditions, the amounts of cytoplasmic c-Rel were similar in all
three groups of mice. Furthermore, the induction of Bcl-xL and
cyclin D2 after BCR stimulation, which was blocked in Btk-defi-
cient B cells, was partially restored in K430R-Btk transgenic mice
(Fig. 7C).
FIGURE 4. Analysis of IL-7-driven BM cultures from Btk mutant mice.
A, Proliferative response to IL-7, as determined by [3H]thymidine incor-
poration after 5 days of culture in the presence or absence of 100 U/ml
IL-7. B, The distribution profile over the indicated B-lineage subpopula-
tions of day 5 IL-7-driven total BM cultures of the Btk mutant mice. Error
bars are the SEM values from four to seven mice per group.
FIGURE 5. Partial correction of mature B cell function in K430R-Btk
mice. A, Serum concentrations of IgM and IgG3 in Btk and Btk mice,
as well as K430R-Btk mice on the Btk and Btk background. Mice were
2 mo of age, total Ig levels were determined by ELISA, and each symbol
indicates an individual mouse (n 5–7). B, Serum concentrations of TNP-
specific IgM and IgG3 7 days after in vivo TNP-Ficoll injection. For each
serum dilution, the ODs are shown as mean values from 11–23 mice in
each group.
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In summary, these results show that in mature B cells, K430R-
Btk is able to transmit BCR signals that can activate NF-B and
induce Bcl-xL and cyclin D2 expression, leading to cell cycle en-
try, proliferation, and rescue from apoptosis.
Discussion
In vivo structure-function analysis for Btk
The characterization of 400 unique human Btk mutations, 155 of
which represent missense mutations, in XLA families could in
principle have allowed the identification of in vivo structure-func-
tion effects of Btk. However, there is phenotypical heterogeneity
among patients, even from single XLA pedigrees, and to date no
correlation has been described between the type and position of the
mutations and clinical or immunological XLA phenotype (38).
Furthermore, the almost complete pre-B cell arrest in most XLA
patients (6) complicates the analysis of the function of the indi-
vidual Btk domains in developmental stages beyond the large 
pre-B cell. As a result, the role played by the various Btk domains
in vivo in humans remained largely unknown.
Analyses in the mouse to date have focused on the in vivo func-
tion of the Btk PH domain, which was shown to be absolutely
essential in mature B cells. This was inferred from the finding of
the same xid phenotype in CBA/N mice with the classical R28C
PH domain mutation and in mice with a complete ablation of Btk
protein generated by gene targeting (8–10). Apparently, the R28
residue in the PH domain is also essential for Btk function in pre-B
cells, as we observed that, comparable to Btk-deficient pre-B cells,
also xid CBA/N pre-B cells manifested an impaired modulation of
the phenotypic markers BP-1, SLC, CD2, and CD25, and an in-
creased proliferative response to IL-7 (S. Middendorp and R. Hen-
driks, unpublished results).
By using transgenic mice expressing Y223F and K430R mutant
Btk, we now demonstrate a differential role of Y223 phosphory-
lation and Btk catalytic activity in developmental progression of
cytoplasmic  pre-B cells in vivo. In particular, we analyzed  L
chain usage; the modulation of BP-1, SLC, CD2, and CD25 ex-
pression; and the IL-7 responsiveness of pre-B cells, all of which
were previously shown to be Btk dependent (14, 16). In this study,
we demonstrate that: 1) the Y223 autophosphorylation site is not
essential for signaling developmental progression of pre-B or B
cells, except for the role of Btk in the regulation of  L chain
usage; 2) in pre-B cells, Btk functions to a large extent as an
adapter molecule; 3) in mature B cells kinase-inactive Btk can
induce the activation of NF-B upon BCR stimulation.
The Y223 autophosphorylation site in the SH3 domain
Although phosphorylation of Y223F has little discernible influence
on Btk catalytic activity, it is generally thought that full activity of
Btk is dependent on phosphorylation of Y223. Y223 is located on
the surface of the SH3 domain, and its phosphorylation prevents
binding to WASP and increases the affinity to Syk (21). The
Y223F mutation dramatically potentiates the transforming activity
FIGURE 6. Partial correction of mature B cell proliferation and survival
in K430R-Btk mice. A, Proliferation, determined by [3H]thymidine incor-
poration, of cells cultured in medium alone, in the presence of LPS, anti-
CD40, or anti-IgM. B, Propidium iodide DNA content analysis of B cells
following stimulation in vitro. Numbers indicate the proportion of cells 	
SEM in the sub-G1 fraction (%) in cell cycle analysis. Data (with mean 	
SEM values from two to four mice per group) are representative of three
independent experiments.
FIGURE 7. K430R-Btk induces NF-B activation upon BCR stimula-
tion. A, SDS-PAGE of in vitro phosphorylated Btk immunoprecipitates
from purified splenic B cells (12  106) from wild-type and K430R-Btk
mice were left untreated or stimulated with anti-IgM for 5 min. For quan-
tification of Btk expression, equal proportions of the immunoprecipitates
were analyzed by Western blotting using Btk-specific Abs. In agreement
with a previous report (42), wild-type Btk showed detectable kinase ac-
tivity also in unstimulated splenic B cells. B, Western analysis of nuclear
and cytoplasmic c-Rel expression. Equal numbers of purified splenic B
cells from the indicated mice were left untreated or stimulated with anti-
IgM for 4 h (left). Induction of nuclear c-Rel was quantified by densitom-
etry, and results are shown as mean values and SEM from four mice per
group (right). C, Induction of Bcl-xL and cyclin D2. Total splenocytes of
the indicated mice were stimulated with anti-IgM and evaluated for the
expression of Bcl-xL and cyclin D2 by immunoblotting using specific Abs.
Membrane was reblotted with anti-extracellular signal-regulated kinase.
Data are representative of four mice analyzed per group.
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of the gain-of-function mutant E41K-Btk in fibroblasts (19). More-
over, the SH3 domain has specificity for the N-terminal proline-
rich region of the Btk TH domain, and therefore it has been hy-
pothesized that intra- or intermolecular interaction between the TH
and SH3 domain might have an important regulatory function (1).
With the exception of  L chain usage, we found that expression
of Y223F-mutated Btk fully corrected all features of the Btk-de-
ficient phenotype, including pre-B cell maturation, differentiation
of peripheral B cells, and B-1 cell development. Furthermore, we
observed reconstitution of B cell function, both in total serum IgM
and IgG3 levels, TI-II responses in vivo, and in proliferative re-
sponses to anti-IgM stimulation in vitro (R. Hendriks, unpub-
lished). Taken together, these results indicate that Y223 autophos-
phorylation-dependent interactions are not essential for B cell
development and mature B cell function. This is consistent with
previous observations that reconstitution of Btk-deficient chicken
DT 40 B cells with Y223F and WT Btk resulted in a similar rescue
of BCR-induced PLC- phosphorylation and calcium flux (39).
Our findings may also explain the remarkable absence of missense
mutations in the Btk SH3 domain in a total of 155 missense mu-
tations identified to date in XLA families (38), while on the basis
of SH3 domain size10 of these should be located within the SH3
domain. Nevertheless, the Y223 autophosphorylation site appears
to be involved in the regulation of  L chain usage. In this context,
it is tempting to speculate that transcription factor II-I (TFII-I) is
involved in the activation of the  L chain locus for recombination,
as the Y223F-Btk mutation also abrogates phosphorylation of a
Btk substrate, the NF BAP-135/TFII-I (40). Obviously, additional
experiments are required to demonstrate whether TFII-I plays any
role in the regulation of gene rearrangements at the  L chain
locus.
It is intriguing that mutation of the Y223 Btk autophosphoryla-
tion site partially affected  L chain usage, while expression of
kinase-inactive Btk restored  usage completely. This may imply
that the Y223F mutation does not only change the interaction of
Btk with proteins that bind to the SH3 domain when phosphory-
lated at Y223, but also with proteins that bind to nonphosphory-
lated Y223, such as c-Cbl and WASP (21). Alternatively, the ob-
tained results could be explained by a contribution of other kinases
to phosphorylation of Btk at position Y223 in vivo, once Btk is
recruited to the pre-BCR signaling complex.
The kinase-inactive K430R-Btk mutant
The K430R mutation destroys the ATP-binding site, resulting in
kinase-inactive Btk (19, 20). Expression of physiological levels of
kinase-inactive Btk in early B cell development normalized  L
chain usage and partially reconstituted the impaired pre-B cell dif-
ferentiation and IL-7 responsiveness in Btk-deficient mice. These
findings imply that Btk partially functions as an adapter molecule,
independent of its kinase activity, possibly in a larger complex
together with other molecules that interact with Btk (Fig. 1A).
Such a complex might include PTK that either bind directly to Btk,
such as Fyn, Lyn, Hck, and Syk, or indirectly through the BLNK/
SLP65 linker molecule, which binds to the Btk SH2 domain. It is
therefore possible that Syk may partially compensate for kinase-
inactive Btk and phosphorylate PLC-2 in a complex that contains
activated BLNK/SLP65 and Btk. Our data indicate that, especially
in the activation of the  L chain locus for V(D)J recombination in
pre-B cells, Btk mainly acts as an adapter molecule. Likewise, in
mature B cells, the role of Btk in proliferation and survival upon
LPS and anti-CD40 stimulation in vivo was found to be fully in-
dependent of Btk enzymatic function. Nevertheless, the (incom-
plete) induction of NF-B, Bcl-xL, and cyclin D2 by K430R-Btk
cannot fully rescue B cell development, as is particularly clear
from the lack of reconstitution of the B-1 cell compartment and in
vivo TI-II responses. In this context, it was recently shown that Btk
participates in NF-B induction by Toll-like receptor 4, whereby
K430R-Btk acts as a dominant-negative inhibitor of the LPS-in-
duced activation of NF-B in an astrocytoma and a monocytic cell
line (41). Taken together, these findings illustrate that the impor-
tance of the Btk kinase domain varies between the different Btk-
mediated signaling pathways during B cell development and be-
tween the different signal transduction pathways.
In summary, our findings demonstrate the differential require-
ment for Btk domains in the developmental progression of cyto-
plasmic  H chain-positive pre-B cells. We show that the regula-
tion of Ig  L chain usage is Y223 dependent, but K430
independent, and that the modulation of pre-B cell marker expres-
sion is Y223 independent, but partially K430 dependent. None of
the two residues appear to be essential for Btk function in the
regulation of IL-7 responsiveness. We therefore conclude that the
control of lg  L chain usage, pre-B cell marker phenotype, and
IL-7 responsiveness involve different downstream signaling path-
ways or molecules interacting with Btk.
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